Abstract :
Background: Cytokine storm is the most life-threatening complication of COVID 19. This retrospective observational study explores efficacy of broad-spectrum serine protease inhibitor ulinastatin for treatment of COVID 19 associated cytokine storm.
Materials and Methods: This retrospective observational study evaluated medical records of COVID 19 patients admitted between January 2022 and April 2022 for use of ulinastatin. A total of sixty-six patients were treated with ulinastatin along with standard care and thirty-six patients only with standard care.
Conclusion: The study concludes that the use of ulinastatin is associated with favorable outcome in COVID 19 cytokine storm. Ulinastatin, the advantage over steroid is anti-inflammatory effect but no adverse effect like immunosuppression, hyperglycemia, high blood pressure and psychosis. Inflammatory markers IL6, ferritin, D dimer, CRP, LDH, NLR ratio whose testing kits are freely available are good predictors of cytokine storm.
Keyword :
Serine protease inhibitor, ARDS, COVID 19 associated cytokine storm, Ulinastatin